Compare WTBA & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTBA | IMMX |
|---|---|---|
| Founded | 1893 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.9M | 306.2M |
| IPO Year | 2002 | 2021 |
| Metric | WTBA | IMMX |
|---|---|---|
| Price | $24.39 | $8.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $24.00 | $13.00 |
| AVG Volume (30 Days) | 43.1K | ★ 735.7K |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 4.05% | N/A |
| EPS Growth | ★ 35.21 | 14.61 |
| EPS | ★ 1.92 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.69 | N/A |
| Revenue Next Year | $9.18 | N/A |
| P/E Ratio | $12.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.33 | $1.34 |
| 52 Week High | $26.60 | $8.97 |
| Indicator | WTBA | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 47.34 | 64.00 |
| Support Level | $23.57 | $1.96 |
| Resistance Level | $26.60 | N/A |
| Average True Range (ATR) | 0.83 | 0.58 |
| MACD | -0.22 | 0.01 |
| Stochastic Oscillator | 32.00 | 70.54 |
West Bancorp Inc is a United States-based company that offers a full range of deposit services, including checking, savings and money market accounts and time certificates of deposit. West Bank also offers online banking, mobile banking, and treasury management services, which help to meet the banking needs of its customers. Treasury management services offered to business customers include cash management, client-generated automated clearing house transactions, remote deposit, and fraud protection services. Also offered are merchant credit card processing and corporate credit cards. The bank operates only in the United States of America region.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.